Boise Cascade Company (NYSE:BCC) ended the last trading day at $25.64. Company weekly volatility is calculated as 3.07% and price to cash ratio as 5.16. Boise Cascade Company (NYSE:BCC) showed a weekly performance of -10.82%.
Boise Cascade Company is a plywood and engineered wood products (EWP) manufacturer and building materials distributor. The Company’s segments include Wood Products and Building Materials Distribution. Its Wood Products segment manufactures plywood, EWP, studs, particleboard and ponderosa pine lumber.
Analysts at Zacks have given a short term rating of strong sell on Boise Cascade, L.L.C. (NYSE:BCC) with a rank of 5.
The Manitowoc Company, Inc. (NYSE:MTW) ended the last trading day at $14.57. Company weekly volatility is calculated as 2.79% and price to cash ratio as 29.39. The Manitowoc Company, Inc. (NYSE:MTW) showed a weekly performance of -8.25%.
The Manitowoc Company, Inc. (MTW) is a multi-industry capital goods manufacturer. The Company operates in two markets: Cranes and Related Products (Crane) and Foodservice Equipment (Foodservice). Crane is a provider of engineered lifting equipment for the global construction industry, including lattice-boom cranes, tower cranes, mobile telescopic cranes and boom trucks.
The Manitowoc Company, Inc. (NYSE:MTW) announced that Glen Tellock, Chairman & Chief Executive Officer, and Steve Khail, Director of Investor Relations & Corporate Communications, participated in a moderator-lead discussion at the Morgan Stanley Laguna Conference at the Montage Laguna Hotel, Laguna Beach, California, on September 16, 2015 at 4:15 p.m., Pacific time.
On 28 September, AXIS Capital Holdings Limited (NYSE:AXS) shares moved down -1.38% and was closed at $54.24. AXS EPS growth in last 5 year was 18.90%. AXIS Capital Holdings Limited (NYSE:AXS) year to date (YTD) performance is 7.35%.
AXIS Capital Holdings Limited is a Bermuda-based holding company for the AXIS group of companies. The Company provides a range of specialty (re)insurance, through operating subsidiaries and branch networks -based in Bermuda, the United States, Canada, Europe, Australia and Singapore.
Axis Capital Holdings (NYSE:AXS) had declared a cash dividend of $0.2900 on Sep 11, 2015. The shares will quote ex-dividend on Sep 28, 2015 and the record date has been fixed on Sep 30, 2015. At Sep 11, 2015 share price, the yield comes out to be 2.1450%. The dividend payable date has been fixed on Oct 15, 2015.
Cytori Therapeutics, Inc. (NASDAQ:CYTX) shares increased 2.33% in last trading session and ended the day at $0.37. CYTX Gross Margin is 66.40% and its has a return on assets of -89.60%. Cytori Therapeutics, Inc. (NASDAQ:CYTX) quarterly performance is -34.21%.
Cytori Therapeutics, Inc. (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury.
Cytori Therapeutics (NASDAQ: CYTX) announced the publication today of the results from the 12 month clinical follow up of patients enrolled in the Scleradec-I clinical trial from hand dysfunction common in patients with the rare disease scleroderma. The Scleradec-I trial, an investigator-initiated, open-label 12 patient trial, was led by Dr. Brigitte Granel and Dr. Guy Magalon from the Assistance Publique des Hôpitaux de Marseille. The manuscript was published in the journal
Galena Biopharma Inc (NASDAQ:GALE) caters to the Healthcare space. Its weekly performance is -15.96%. On the last day of trading company shares ended up at $1.58. Galena Biopharma Inc (NASDAQ:GALE) distance from 50-day simple moving average (SMA50) is -2.18%.
Galena Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets, including immunotherapy program led by its lead product NeuVax (nelipepimut-S), which is in Phase III clinical trial and is a targeted cancer immunotherapy.
Galena Biopharma, Inc. (GALE) announced that data from the GALE-301 Phase 2a portion of the Phase 1/2a clinical trial was presented at the European Cancer Congress 2015 in Vienna, Austria. GALE-301 is Galena’s cancer immunotherapy that consists of a peptide derived from Folate Binding Protein.
Leave a Reply